Latest estradiol Stories
New dose approved by FDA for the prevention of postmenopausal osteoporosis only; higher doses of Minivelle can also treat moderate to severe hot flashes due to menopause MIAMI and
PITTSBURGH, Dec. 22, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S.
Apparently women aren't the only ones who can use the "pregnant, mommy brain" excuse.
Minivelle now approved for prevention of postmenopausal osteoporosis at all doses MIAMI and NEW YORK, Sept. 24, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc.
As Merck Moves Forward to Resolve 3,800 Pending NuvaRing Lawsuits in the U.S., Health Canada Issues Safety Alert for the Contraceptive NuvaRing Citing It May Be Harmful for Some Women
NEW YORK, July 15, 2014 /PRNewswire/ -- According to BCC Research, the global market for women's health therapeutics is expected to reach $22.5 billion in 2018.
New offering through an agreement with Meda AB expands Mission's women's healthcare options SAN ANTONIO, May 29, 2014 /PRNewswire/ --
A new research study from Brigham and Women's Hospital (BWH) that compares low-dose oral estrogen and low-dose non-hormonal venlafaxine hydrochloride extended release (XR) to placebo were both found effective in reducing the number of hot flashes and night sweats reported by menopausal women.
DUBLIN, April 16, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/q7jzmk/sustained_release) has announced the addition of the "Concise
- Large; stout; burly.